ANZCTR search results

This study aims to evaluate whether treatment with 1 GBq of radioactive iodine (RAI) is as effective as 4 GBq of RAI in patients with intermediate-risk or high-risk papillary thyroid cancer. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with non-metastatic papillary thyroid cancer, and your cancer has been determined to be BRAF-positive (a specific genetic sub-type of this cancer). Study details Participants who choose to enrol in this study will be randomly allocated by chance (similar to flipping a coin) to one of two treatment groups. Participants allocated to the first group will be asked to take a 1 GBq dose of radioactive iodine. Participants allocated to the second group will be asked to take 4 GBq dose of radioactive iodine. Participants in both groups will then be asked to complete blood tests and imaging of their thyroid every 3 months after their first dose for a 12 months. It is hoped this research will determine whether a 1 GBq dose of RAI is as effective or at least not any less effective than 4 GBq of RAI. If this study shows that a low dose of RAI is as effective as a high dose of RAI, this may be expanded to a larger study involving more patients with papillary thyroid cancer.

This pilot study is testing a new support service called "While We Wait", designed specifically for adolescents aged 14 to 17 years who are waiting for mental health treatment as referred by their General Practitioner (GP). The study will explore whether this new service is practical to deliver, whether young people, their families, and GPs find it helpful and easy to use, and whether it provides any early psychological benefits or causes any problems. The research team will focus on the feasibility and acceptability, preliminary benefits to mental health, as well as the safety of the intervention.

This study will evaluate whether low-intensity support helps schools sustain delivery of the Physical Activity 4 Everyone (PA4E1) program—a proven initiative supporting schools to implement seven practices that boost student physical activity. We will compare schools receiving light touch sustainment support to those receiving usual support, assessing how many physical activity practices are maintained at the end of active implementation (baseline), and at 12- and 24-month follow-ups.

Pulmonary embolism (blood clots in the lungs) is a common, potentially life-threatening condition affecting 50 to 75 per 100,000 people each year in Australia. The current long-term treatment of blood clots is limited to blood thinners alone, and there are no other studies investigating different treatment approaches. Mechanisms that determine persistence of blood clots in the lung blood vessels despite adequate blood thinning treatment remain unknown. Inflammation within the blood vessel walls following a blood clot seems to be an important driver of impaired clot resolution, but treatments targeting inflammation within the blood vessels are limited. Glucagon-like peptide-1 (GLP-1) agonists, which are commonly used in diabetes treatment, have prominent anti-inflammatory and blood vessel relaxation properties supporting their use in patients with lung blood clots at higher risk of worse outcomes. The purpose of this study is to test a novel treatment approach with a once-a-day medication (Liraglutide), in hospitalised patients with acute lung blood clots.

Brief description of the study purpose This study is testing whether a newer biopsy technique, called cryobiopsy, can be used on its own to accurately diagnose lung nodules. It will also look at whether the order in which different biopsy methods are performed affects the accuracy of the diagnosis. Who is it for? You will be eligible if you are an adult who are scheduled to have a bronchoscopy with radial endobronchial ultrasound (R-EBUS) at Westmead Hospital or Westmead Private Hospital may be able to take part. Study details All participants who are eligible will undergo a bronchoscopy procedure using R-EBUS as part of their routine care. During this procedure, several different biopsy techniques will be performed: up to 6 forceps biopsies, 3 fine needle aspirations, 1 brushing, and up to 5 cryobiopsies. The order of sampling will be randomised. The tissue samples will be examined by pathologists to see which technique provides the most accurate diagnosis. It is hoped this research will show whether cryobiopsy can replace other methods, improving the accuracy and efficiency of diagnosing lung nodules and helping patients receive the right treatment sooner.

A large proportion of INOCA (ischaemia with non-obstructive coronary arteries) patients continue to have symptoms despite being on multiple medications. Sildenafil was studied in a small international study in 2011 which showed some early promising results. However, to the best of our knowledge, there have been no subsequent studies using Sildenafil to treat INOCA. The purpose of this study is to see if Sildenafil improves INOCA symptoms.

PRISM is a prospective registry and biorepository, established to facilitate the collection of clinical data and biospecimens with the aim of improving infection prevention, infection surveillance and infection management in patients receiving disease modifying therapies for autoimmune conditions. Research questions which may be address relate to the real-world epidemiology of infections in patients receiving disease modifying therapies, impact of disease modifying therapies on vaccine response, and the effect of sequential immunological therapies on the immune system.

This is a prospective observational exploratory study investigating the immunological effects of RSV vaccination in pregnant women. All pregnant women will receive a single dose of the Abrysvo RSV vaccine. Detailed exploratory systems biology assays (transcriptomics, epigenetics, lipidomics, metabolomics) and flow cytometry will be performed to investigate the broad immunomodulatory effects of RSV vaccination.

This study aims to find out whether adding an opioid painkiller (tapentadol) to standard pain relief (paracetamol and ibuprofen) provides better pain control than using standard pain relief alone after surgery for broken bones. Adults who have had surgery for a fracture will be randomly assigned to receive either tapentadol or a placebo for breakthrough pain during the first week after leaving hospital. The study will measure pain levels, recovery, and any side effects to help determine the safest and most effective way to manage pain after surgery following hospital discharge.

This study is testing a new support program called Transition Compass to help young people with long-term health conditions transition smoothly from children’s to adult healthcare services. Who is it for? You may be eligible for this study if you are aged 16 to 21 and have a long-term health condition diagnosed in childhood, such as cancer, diabetes, asthma, or epilepsy. You should have been receiving specialist paediatric care for at least two years and be approaching discharge to adult healthcare services. You should also be expected to continue receiving regular specialist care for at least two more years. Study details Participants in this study will be allocated to one of two groups by chance: 1. Current usual care as provided by their treating paediatric and adult health services. This may include standard discharge planning, referrals, and follow-up arrangements. 2. A mobile-based support program, called "Transition Compass" to support the transition from children’s to adult healthcare. The program includes supportive messages, access to a transition coach, and monthly educational videos to guide participants through topics such as managing their health, navigating adult services, and staying well during the transition. Participants will be followed for two years. Information will be collected on ongoing engagement with healthcare services, including attendance at regular appointments with adult specialists, any hospitalisations or emergency visits, and participants’ experience of the transition process, including satisfaction with care. It is hoped that this research will help determine if Transition Compass improves outcomes for young Australians with chronic illness, improves patient experience and helps guide future healthcare policy.